Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EPS (Basic) (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed EPS (Basic) for 5 consecutive years, with -$0.42 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) fell 182.35% to -$0.42 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.75 through Dec 2025, down 2600.0% year-over-year, with the annual reading at -$1.74 for FY2025, 2275.0% down from the prior year.
  • EPS (Basic) hit -$0.42 in Q4 2025 for ARS Pharmaceuticals, up from -$0.52 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $1.19 in Q4 2021 to a low of -$0.7 in Q2 2021.
  • Historically, EPS (Basic) has averaged -$0.19 across 5 years, with a median of -$0.28 in 2025.
  • Biggest five-year swings in EPS (Basic): surged 828.57% in 2024 and later tumbled 253.85% in 2025.
  • Year by year, EPS (Basic) stood at $1.19 in 2021, then decreased by 25.21% to $0.89 in 2022, then tumbled by 107.87% to -$0.07 in 2023, then soared by 828.57% to $0.51 in 2024, then tumbled by 182.35% to -$0.42 in 2025.
  • Business Quant data shows EPS (Basic) for SPRY at -$0.42 in Q4 2025, -$0.52 in Q3 2025, and -$0.46 in Q2 2025.